GenMark Diagnostics, Inc
GNMK
GNMK was delisted on the 21st of April, 2021.
90 hedge funds and large institutions have $577M invested in GenMark Diagnostics, Inc in 2016 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 37 increasing their positions, 24 reducing their positions, and 12 closing their positions.
54% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 24
3% more capital invested
Capital invested by funds: $559M → $577M (+$17.6M)
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
1% less funds holding
Funds holding: 91 → 90 (-1)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.08M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.54M |
| 3 |
Jennison Associates
New York
|
+$4.06M |
| 4 |
Millennium Management
New York
|
+$3.82M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$3.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
-$6.4M |
| 2 |
Morgan Stanley
New York
|
-$6.12M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$5.87M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.16M |
| 5 |
CCM
Cadian Capital Management
New York
|
-$3.82M |
GNMK Hedge Fund Activity: Q4 2016 in Review
90 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in GenMark Diagnostics, Inc (GNMK) for Q4 2016, worth a combined $577M — up 3.2% from $559M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of GNMK and 11 opened new positions — a net loss of 1 holder — while 24 trimmed existing stakes and 37 added.
The largest buyer was Fidelity Investments, adding an estimated $6.08M. The largest seller was Northpointe Capital, cutting an estimated $6.4M.
- 90 institutional investors held GenMark Diagnostics, Inc (GNMK) as of Q4 2016, down from 91 in Q3 2016.
- Funds reported $577M of GenMark Diagnostics, Inc stock for Q4 2016, up 3.2% quarter-over-quarter.
- 11 funds opened new GenMark Diagnostics, Inc positions in Q4 2016 and 12 closed out, a net change of -1 holder.
- The largest GenMark Diagnostics, Inc buyer in Q4 2016 was Fidelity Investments, an estimated $6.08M added.
- The largest GenMark Diagnostics, Inc seller in Q4 2016 was Northpointe Capital, an estimated $6.4M sold.
Based on aggregated 13F filings for Q4 2016.